Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
2.55% $25.32
America/New_York / 19 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 1 939.71 mill |
EPS: | -8.37 |
P/E: | -3.03 |
Earnings Date: | Apr 25, 2024 |
SharesOutstanding: | 76.61 mill |
Avg Daily Volume: | 0.906 mill |
RATING 2024-04-19 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Sell | |
Return On Equity: | Strong Buy | |
Return On Asset: | Sell | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -3.03 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.52x |
Company: PE -3.03 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 23.76 - 26.88 ( +/- 6.15%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-17 | Pauwels Eric | Sell | 787 | Common Stock |
2024-04-17 | Klein Matthew B. | Sell | 1 307 | Common Stock |
2024-04-02 | Golden Lee Scott | Sell | 526 | Common Stock |
2024-02-15 | Utter Christine Marie | Buy | 2 900 | Common Stock |
2024-02-15 | Utter Christine Marie | Buy | 14 000 | Common Stock |
INSIDER POWER |
---|
73.84 |
Last 98 transactions |
Buy: 1 039 271 | Sell: 201 078 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $25.32 (2.55% ) |
Volume | 3.93 mill |
Avg. Vol. | 0.906 mill |
% of Avg. Vol | 433.79 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $25.29 | N/A | Active |
---|
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.